Immunogenicity and safety of the 9-valent human papillomavirus vaccine in Chinese females 9–45 years of age: A phase 3 open-label study

•The 9vHPV vaccine is currently approved for use in Chinese women aged 16–26 years.•Immunogenicity was compared: 9–19- and 27–45- vs. 20–26-year-old Chinese females.•Antibody responses were non-inferior in 9–19- and 27–45- vs. 20–26-year-olds.•Data support bridging of efficacy to Chinese females aged 9–19 years and 27–45 years.•The 9vHPV vaccine was generally well tolerated in Chinese females aged 9–45 years.